

Silurian Pharmaceuticals, Inc. to present at the North American Cystic Fibrosis Conference, Orlando, Florida

Silurian will present recent results of its drug Brevenal for the treatment of defective mucociliary clearance and the prevention of exacerbations in Cystic Fibrosis, at the NACFC, Orlando, Florida, October 27-29, 2016.

Brevenal is a promising new therapy for patients with cystic fibrosis. Low doses reverse the inhibition of airway mucociliary function caused by CFTR inhibitor 172 and human neutrophil elastase (HNE) in sheep. It also alleviates bronchoconstriction caused by HNE. This demonstrates that brevenal's activity is independent of CFTR, as well as it addresses the downstream pulmonary complications cause by HNE.


More so, it appears that brevenal's effect on mucociliary function is superior to currently used therapies in CF patients.

We are excited about the progress made with Brevenal and the ongoing positive results obtained from our drug candidate in both *in vivo* and *in vitro* CF models. Brevenal shows efficacy, in these models, alone and in combination with Orkambi™ and Kalydeco™. Our studies demonstrate that Brevenal increases ASL secretion in donor CF human bronchial epithelium cells and this effect is additive to when used with Orkambi™. More so, Brevenal, unlike Orkambi™, blocks decrease in ASL when CF HBE cells are challenged by the inflammatory cytokine TGFβ1.

All the *in vitro* data in donor CF HBE cells were confirmed in the sheep airway challenge model. When ineffective doses of Brevenal and aerosol Kalydeco™ were administered to sheep challenged with CFTR(inh)- 172 alone or in combination with human neutrophil elastase, simulating CF airways, they demonstrated additive effect in reversing inhibited mucociliary clearance. More so, Brevenal also reversed CFTR(inh)- 172 in combination to TGFβ1 induced mucociliary clearance inhibition.

We will be presenting three abstracts during the meeting:

79 (Oral Presentation) Abstract Title: Brevenal is Comparable to Aerosol Ivacaftor in Reversing the Slowed Down Mucus Transport Induced by Airway Challenge with CFTR(inh)-172 Alone or in Combination with Human Neutrophil Elastase in Sheep.





This abstract will be presented by William Abraham, PhD, Mount Sinai Medical Center, Miami Beach, FL, on Friday, October 28, 2pm- 3:20pm, Workshop Session II: APP&D: Mucins & Mucus in CF.

#80 Abstract Title: Brevenal Reverses Mucociliary Dysfunction in Sheep Challenged with CFTR(inh)-172 + TGF β 1 and Blocks Decrease in ASL in TGF β 1 Challenged CFHBE Cells

The poster (with the poster for #79) will be presented in Airways Physiology, Pathophysiology & Defense section, Thursday, October 27, 11:15am- 1:45pm.

#265 Abstract Title: Brevenal Increases Airway Surface Liquid in F508Del HBE Cells

The poster will be presented in New Therapies, Biomarkers & Outcome Measures section, Friday, October 28, 4pm- 6pm.

About Silurian Pharmaceuticals, Inc.

Silurian Pharmaceuticals, Inc. is dedicated to the development of new approaches for the treatment of pulmonary disorders in CF and COPD. Silurian harnesses the discovery of the novel polyketides from Marine organisms.

Silurian Pharmaceuticals, Inc., 6085 Grizzly Peak Blvd., Oakland, CA 94611 www.silurianpharma.com

